Lukang Pharmaceutical announced that Shandong Lukang Pharmaceutical Group Saite Co., Ltd., a holding subsidiary of the company, recently received the “Drug Supplement Application Approval Notice” for Clariboron Ointment approved and issued by the State Drug Administration, agreeing that Sete will be the holder of the above drug marketing license, and that the drug marketing license holder will be changed from Zhejiang Symer Pharmaceutical Co., Ltd. to Saite. As of the announcement date, Sete has invested a total of about 7.66 million yuan in the drug technology transfer project.

Lukang Pharmaceutical announced that Shandong Lukang Pharmaceutical Group Saite Co., Ltd., a holding subsidiary of the company, recently received the “Drug Supplement Application Approval Notice” for Clariboron Ointment approved and issued by the State Drug Administration, agreeing that Sete will be the holder of the above drug marketing license, and that the drug marketing license holder will be changed from Zhejiang Symer Pharmaceutical Co., Ltd. to Saite. As of the announcement date, Sete has invested a total of about 7.66 million yuan in the drug technology transfer project.